<DOC>
	<DOCNO>NCT00063479</DOCNO>
	<brief_summary>The primary purpose trial evaluate whether investigational medication safe , effective ability increase spine bone density osteogenesis imperfecta ( OI ) patient .</brief_summary>
	<brief_title>Bisphosphonate Treatment Osteogenesis Imperfecta</brief_title>
	<detailed_description />
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion Male Female child 3 month 17 year old OI type I , III IV Exclusion Deformity abnormality would prevent spine bone density do Any surgical bonelengthening procedure Any kidney disease abnormality Low calcium vitamin D level blood Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Osteogenesis Imperfecta</keyword>
	<keyword>OI</keyword>
	<keyword>bone marker</keyword>
	<keyword>fracture</keyword>
	<keyword>bone loss</keyword>
	<keyword>pediatric</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>brittle bone disease</keyword>
	<keyword>pamidronate</keyword>
</DOC>